Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Park who wrote (25135)	12/9/1998 8:37:00 PM
From: Cape Cod Charlie	Read Replies (3) \| Respond to of 119973

Better than making money--someday soon ASTM might save one of our loved ones lives. Now thats a great company. I wish you guys would stop trying to keep this a secret and TELL SOMEBODY. LOL

To: Mr. Park who wrote (25135)	12/9/1998 8:51:00 PM
From: DO$Kapital	Read Replies (1) \| Respond to of 119973

From DECEMBER 2ND: <<<ANN ARBOR, Mich., Dec 2 (Reuters) - Aastrom Biosciences Inc. said Wednesday that it started a pivotal clinical trial with its AastromReplicell Cell Production System to provide an alternative method of cell collection for cancer patients requiring an autologous stem cell transplant. Results from an earlier trial, completed under an investigational device exemption from the U.S. Food and Drug Administration, were positive, the company said. Chief Executive Douglas Armstrong said, "The pivotal trial represents an extension of the earlier trial ... We believe the subsequent trial results will further demonstrate the clinical utility of the AastromReplicell System." AastromReplicell is designed to produce cells useful in a broad range of therapies. Stem cell transplants are commonly used to treat patients with cancer or other diseases who have undergone extensive chemotherapy or radiation treatments. These treatments can damage or destroy the patient's bone marrow and blood and immune system cells. As a result, these patients sometimes need a stem cell transplant to restore their vital cells and tissues, Aastrom said. The AastromReplicell is an automated clinical system for producing hard-to-collect therapeutic cells from small starting quantities. >>>